CURRICULUM VITAE

ANDREW C. ROSENTHAL (LOWY)

JUNE 2008

PERSONAL DETAILS

Name: Andrew Curt Rosenthal

Address: 26/4 Mitchell Road

Darling Point NSW 2027

Telephone: (61 2) 9362 1966 (home)

(61 414) 908 809 (mobile)
Facsimile: (61 2) 9362 1900

Email: andrew@acrc.com.au

Date of birth: 14 November 1966

Place of birth: Sydney, Australia

Marital Status: Single

Languages spoken: English

French (basic conversation)

Medical Registration
Number: MPO: 265930

ACADEMIC HISTORY

1972–1984: Sydney Grammar School

Higher School Certificate, 1984
1985–87: University of New South Wales: medical student (Years 1-3)
1988: Department of Neurology, Prince Henry Hospital:
Bachelor of Medical Science (research/thesis)
1989–90: Medical student (Years 4-5)

Academic qualifications:

1989: Bachelor of Medical Science (UNSW)

1991: Bachelor of Medicine, Bachelor of Surgery (UNSW)
1998: FRACP Part 1
2000: FRACP Part 2 (Endocrinology)
2003: FRACP (Clinical Pharmacology – Cardiovascular)
 CLINICAL EXPERIENCE

1991: Intern, Royal Prince Alfred Hospital, Sydney

1992: Resident Medical Officer, Prince Henry and Prince of Wales

Hospitals, Sydney

1993: Psychiatry Registrar, Prince of Wales Hospital and London, UK

1994: Psychiatry Registrar, Prince Henry Hospital

1995: Medical Registrar, Prince Henry and Prince of Wales Hospitals

1996: Medical Registrar, St George Hospital, Sydney

1997: Medical Registrar, St George Hospital, Sydney

1998: Endocrinology/Diabetes Registrar, St Vincent’s Hospital,

Sydney

1999: Senior Endocrinology Registrar, St Vincent’s Hospital, Sydney

2000: Senior Endocrinology Registrar, Concord Hospital, Sydney;

Research Registrar in Clinical Pharmacology, St George Hospital, Sydney

2001: Clinical Research Physician/Clinical Pharmacology Registrar,

Department of Clinical Pharmacology, St George Hospital, Sydney
Locum Staff Specialist, Department of Clinical Pharmacology,
St George Hospital, Sydney (part-time)
Consultant Endocrinologist in private practice, Sydney

2002–3: Staff Specialist (Clinical Research), Department of Clinical Pharmacology,

St George Hospital, Sydney (fractional 0.3)
Honorary Medical Officer, Diabetes Centre, St Vincent’s Hospital, Sydney
CEO & Principal Investigator, Australian Clinical Research Centre, Sydney
Consultant Endocrinologist in private practice

2004–8: Visiting Medical Officer (Endocrinology), and Chairman, Drugs & Therapeutics
Committee (from 2007), The Sutherland Hospital, Caringbah
Honorary Medical Officer, Diabetes Centre, St Vincent’s Hospital, Sydney
Consultant Endocrinologist in private practice
CEO & Principal Investigator, Australian Clinical Research Centre, Sydney
(see http://acrc.webcoda.net.au/CEOPrincipalInvestigator/tabid/65/Default.aspx for
snapshot)
 BASIC & CLINICAL RESEARCH EXPERIENCE

1. Department of Neurology, Prince Henry/Prince of Wales Hospitals, Sydney (1988)

One year of neuropharmacology research conducted in the Department of Neurology at the Prince
Henry Hospital, leading to the award of Bachelor of Medical Science. The work was supervised by
Professor J W Lance and investigated the pathways involved in the perception of head pain.
Experiments were performed on anaesthetised cats.

2. Metabolism and Obesity Program, Garvan Institute of Medical Research, Sydney (1998)

Participation in ongoing research examining the relationship between muscle lipids and insulin
resistance in humans. This work has been of major clinical relevance to the pathogenesis of type 2
diabetes mellitus.

3. Department of Clinical Pharmacology, St George Hospital, Sydney (2000)

A one-year clinical research project evaluating the effects of cerivastatin (in males) and phyto-
oestrogens (in females) on endothelial function in type 2 diabetes mellitus, in the setting of a double-
blind, randomised, placebo-controlled trial. The studies used forearm blood flow and
plethysmographic techniques to measure the haemodynamic responses to various agents in the
presence of the above drugs. The work was supervised by Professor L G Howes.

4. Department of Clinical Pharmacology, St George Hospital, Sydney (2000 – 2003)

Co-investigator for sponsored clinical trials in areas of hypertension, cardiovascular disease and
diabetes (Principal Investigator: Professor Laurie Howes).

5. Australian Clinical Research Centre, Sydney (2002 – 2008)

CEO & Principal Investigator for sponsored clinical trials (Phase IIa – IV) in diabetes,
endocrinology, cardiovascular medicine (hypertension, dyslipidaemia, atrial fibrillation and CV
outcomes trials) and other areas in internal medicine. (A full list of trials performed, recruitment
success and sponsors (many of which were GSK) is available on request.)
 ICH/GCP training received at numerous Investigator and Site Initiation Meetings since
2000;
 Regular liaising with IRB/HRECs* and the TGA;
 Signing off AEs/SAEs and experience in drug safety/pharmacovigilance

*including the HREC at the Prince of Wales Hospital (SESIAHS – Northern Section) and the
Bellberry (private) HREC

EDITORIAL EXPERIENCE

1. Australian Medicines Handbook: Expert reviewer, Endocrine & Metabolic Drugs (2008 – )
 COMMERCIAL EXPERIENCE

1. Southern Diabetes & Endocrinology (2001–8)

 Successful private general endocrinology practice set up de novo;
 Serviced by four individual endocrinologists simultaneously;
 Well-recognised throughout the local region by general practitioners and patients

2. CEO and Principal Investigator, Australian Clinical Research Centre (ACRC) (2002–8)
 Sponsored clinical trials (mainly, but not exclusively, the cardiovascular/metabolic
therapeutic areas) were performed under contract to virtually every large
pharmaceutical company and CRO (in particular AstraZeneca, Pfizer, MSDA, Novo
Nordisk, Eli Lilly and GSK).
 Employed a team of ten staff in whom a successful team dynamic was fostered under
my leadership to enhance team-building and personnel empowerment, as well as
conflict management (where appropriate or necessary);
 Successfully handled budgets, timelines and utilised strategic thinking oriented
towards business goals, such that ACRC’s operating profit increased exponentially
from 2004 onwards;
 2007 fiscal year turnover in excess of $1 million (extrapolated 2008 higher);
 Sold to Symbion Health Ltd in February 2008

3. Southern Densitometry Centre (2004–08)

 Running of successful private bone densitometry (BMD) practice with leased Lunar
Prodigy™ densitometer;
 This functioned as
o a service to local general practitioners and patients;
o a means of conducting osteoporosis trials
 It was also commercialised for Novartis Pharmaceuticals for the carrying out of a
pilot clinical trial for the non-hospital/clinic use of intravenous zoledronic acid for
osteoporosis
 PUBLICATIONS

1. Lowy A. The pharmacology of the central processing of head pain, BMedSc thesis, University of New
South Wales, 1988

2. Boers P, Lowy A, Lambert GA, Angus-Leppan H, Zagami AS. Effect of ergot alkaloids on cervical spinal
cord neurons with craniovascular input, Soc Neurosci Abstr 1989;15: 187.

3. Lowy AJ, Lambert GA. Effect of ergot alkaloids on cervical spinal cord processing of nociceptive input
from cerebral blood vessels, Neurosci Lett 1989;Supp 34: S109.

4. Lambert GA, Lowy AJ, Boers PM, Angus-Leppan H, Zagami AS. The spinal cord processing of input
from the superior sagittal sinus: pathway and modulation by ergot alkaloids, Brain Research 1992;597:
321-330.

5. Lowy AJ, Sachdev PS, Lindeman R, Wilson AJ. Disseminated intravascular coagulopathy and
thrombocytopenia associated with clozapine-induced neuroleptic malignant syndrome, Aust NZ J Med
1995;25: 368.

6. Chisholm DJ, Poynten AM, Ellis BA, Furler SM, Lowy AJ, Kraegen EW, Campbell LV, Cooney GJ.
Relationship of insulin sensitivity with abdominal fat and muscle long chain acyl CoA’s (LCACs) in men,
Diabetologia 1998;41, Supp 1: 801

7. Poynten AM, Ellis, BA, Furler, SM, Lowy AJ, Kraegen EW, Campbell, LV, Cooney GJ, Chisholm DJ.
Relationship of muscle long chain acyl CoAs (LCACs) and abdominal fat with insulin sensitivity in men,
ADEA/ADS Annual Scientific Meetings, Proceedings, Perth (1998).

8. Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW, Cooney GJ. Long-chain acyl-CoA
esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol
2000;279: E554-E560.

9. Lapsys NM, Kriketos AD, Lim-Fraser M, Poynten AM, Lowy A, Chisholm DJ, Cooney GJ. Expression of
genes involved in lipid metabolism correlate with PPAR- expression in human skeletal muscle. J Clin
Endocrinol Metab 2000;85: 4293-4297.

10. Furler SM, Poynten AM, Kriketos AD, Lowy AJ, Ellis BA, Maclean EL, Kraegen EW, Campbell LV,
Chisholm DJ. Independent influences of central fat and skeletal muscle lipids on insulin sensitivity.
Obesity Res 2001;9: 535-43.

11. Lowy AJ, Chisholm DJ. Insulinoma masked by pregnancy, Intern Med J 2001; 31: 128-129.

12. Lowy AJ, Howes, LG. ACE inhibitors and angiotensin receptor blockers in type 2 diabetes (Review).
Current Therapeutics 2002; 43: 47-51

13. Lowy AJ, Howes, LG. ACE inhibitors and angiotensin receptor blockers in type 2 diabetes (Review). New
Ethicals J 2002; 5: 45-49

14. Howes LG, Lowy A. Selective COX-2 inhibition: cardiovascular consequences (Review). New Ethicals J
2003; 6: 11-16

15. Lowy AJ and Phillips, PJ. Getting to know the glitazones. Medicine Today 2004; 5: 54-65

16. Tran D, Lowy A, Howes JB, Howes LG. The effects of cerivastatin on forearm vascular responses, blood
pressure responsiveness and ambulatory blood pressure in type 2 diabetic men. Diabetes, Obesity and
Metabolism 2005; 7:273-281

17. Phillips P, Lowy A. Focus on Avandamet. Medicine Today 2007; 8: 57-59

 PROFESSIONAL ORGANISATIONS – MEMBERSHIP

1. Australian Diabetes Society (ADS)

2. Endocrine Society of Australia (ESA)

3. Australian & New Zealand Bone & Mineral Society (ANZBMS)

4. Cardiac Society of Australia & New Zealand (CSANZ)

5. Australian Society of Clinical & Experimental Pharmacologists & Toxicologists (ASCEPT)

6. Australian Association of Pharmaceutical Physicians (APPA – pending)

7. American Association of Clinical Endocrinologists (AACE)

8. The (US) Endocrine Society

9. American Diabetes Association (ADA)

10. European Association for the Study of Diabetes (EASD)

11. Fellow, Royal Australasian College of Physicians

12. Diabetes Australia (NSW) Advisory Group

13. Avant Medical Defence

14. Australian Medical Association

 REFEREES

Professor Mark E Cooper

Associate Director; Head, JDRF Diabetes and Metabolism Division
Baker Heart Research Institute
75 Commercial Road
Melbourne VIC 3004
Tel: (03) 8532 1362
Email: mark.cooper@baker.edu.au

Professor Donald J Chisholm, AO

Emeritus Professor of Endocrinology
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst NSW 2010
Tel: (02) 9295 8205
Email: d.chisholm@garvan.org.au

Professor Lesley V Campbell, AM

Professor of Medicine and Director
Diabetes Centre
St Vincent’s Hospital
372 Victoria Street
Darlinghurst NSW 2010
Tel: (02) 8382 2622
Email: l.campbell@garvan.org.au

Professor Richard O Day, AM

Professor of Clinical Pharmacology
Director of Clinical Pharmacology & Toxicology
Executive Director, Clinical Trials Centre
St Vincent’s Hospital
Darlinghurst NSW 2010
Co-Director, NSW Medicines Information Centre
Tel: (02) 8382 2331
Email: r.day@unsw.edu.au

Dr John Miller
Medical Director
Novo Nordisk Pharmaceuticals Pty Ltd
Level 3, 21 Solent Circuit
Baulkham Hills NSW 2153
Tel: (02) 8858 3600
Email: jomi@novonordisk.com

Dr Catharina Dillenbeck
Clinical Quality Manager
AstraZeneca Pty Ltd
Alma Rd
North Ryde NSW 2113
Tel: (02) 9978 3659
Email: catharina.dillenbeck@astrazeneca.com